A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma
Status:
Unknown status
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The study is aimed at evaluating efficacy and safety of oglemilast in the treatment of stable
mild to moderate persistent asthma. The study involves two weeks of run in period. This is a
placebo controlled study. One of the four treatment arms is placebo. The duration of
treatment is 12 weeks.